PMID- 10744076
OWN - NLM
STAT- MEDLINE
DCOM- 20000412
LR  - 20230216
IS  - 0023-6837 (Print)
IS  - 0023-6837 (Linking)
VI  - 80
IP  - 3
DP  - 2000 Mar
TI  - Microsatellite analysis of microdissected tumor cells and 6p high density 
      microsatellite analysis in head and neck squamous cell carcinomas with 
      down-regulated human leukocyte antigen class I expression.
PG  - 405-14
AB  - Down-regulated human leukocyte antigen (HLA) class I expression is frequently 
      correlated with allelic loss at 6p21.3, which is the location of the HLA coding 
      sequence, in head and neck squamous cell carcinomas (HNSCCs). Previously, we have 
      demonstrated loss of heterozygosity (LOH) at 6p21.3 for at least one locus in 49% 
      of the HNSCCs using 5 microsatellite markers spanning the 4 megabase HLA region. 
      In the present study, the detection threshold (25%) to assign LOH was addressed 
      by laser-assisted microdissection of tumor cells from tumors containing marginal 
      loss. In addition, we describe high density microsatellite analysis of chromosome 
      6p21.3 in HNSCC with down-regulated HLA class I expression. The purpose of this 
      study was to refine the identification of genetic alterations at 6p21.3 and to 
      pinpoint allelic loss to individual HLA class I genes, using additional markers 
      closely located to the HLA-A, -B, and -C loci and the transporter associated with 
      antigen processing (TAP) genes. LOH analysis by amplification of microsatellite 
      markers and subsequent fluorescent detection is a rapid and sensitive technique 
      to predict HLA class I loss phenotypes in tumors. LOH can be identified at 25% 
      relative signal reduction. Analysis of heterogeneous tumor samples and samples 
      containing a small amount of tumor cells is facilitated by laser-assisted 
      microdissection of tumor cells. In addition, we showed that accurate HLA LOH 
      analysis requires application of microsatellite markers in close proximity to HLA 
      class I and TAP genes.
FAU - Feenstra, M
AU  - Feenstra M
AD  - Department of Pathology, University Medical Center, Utrecht, The Netherlands.
FAU - Verdaasdonk, M
AU  - Verdaasdonk M
FAU - van der Zwan, A W
AU  - van der Zwan AW
FAU - de Weger, R
AU  - de Weger R
FAU - Slootweg, P
AU  - Slootweg P
FAU - Tilanus, M
AU  - Tilanus M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Lab Invest
JT  - Laboratory investigation; a journal of technical methods and pathology
JID - 0376617
RN  - 0 (DNA Primers)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Base Sequence
MH  - Carcinoma, Squamous Cell/*genetics/immunology/pathology
MH  - *Chromosomes, Human, Pair 6
MH  - DNA Primers
MH  - *Down-Regulation
MH  - Head and Neck Neoplasms/*genetics/immunology/pathology
MH  - Histocompatibility Antigens Class I/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - Loss of Heterozygosity
MH  - Lymphatic Metastasis/genetics
MH  - Microsatellite Repeats/*genetics
MH  - Tumor Cells, Cultured
EDAT- 2000/04/01 09:00
MHDA- 2000/04/15 09:00
CRDT- 2000/04/01 09:00
PHST- 2000/04/01 09:00 [pubmed]
PHST- 2000/04/15 09:00 [medline]
PHST- 2000/04/01 09:00 [entrez]
AID - S0023-6837(22)02209-7 [pii]
AID - 10.1038/labinvest.3780045 [doi]
PST - ppublish
SO  - Lab Invest. 2000 Mar;80(3):405-14. doi: 10.1038/labinvest.3780045.